VBIV VBI Vaccines Inc.

-0.08  -4%
Previous Close 2.05
Open 2.04
Price To Book 1.97
Market Cap 126235199
Shares 64,078,781
Volume 220,236
Short Ratio
Av. Daily Volume 321,057

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2a six-month PFS and OS data due 1H 2019.
Recurrent glioblastoma multiforme (rGBM)
Phase 3 data due mid-2019.
Hepatitis B vaccine
Phase 2 trial to be initiated YE 2019.
Congenital Cytomegalovirus (CMV)
Phase 3 data due YE 2019.
Hepatitis B vaccine

Latest News

  1. VBI Vaccines Appoints Dr. Vlad Popovic as Vice President of Clinical Development and Medical Affairs
  2. VBI Vaccines Appoints Joanne Cordeiro to Board of Directors
  3. VBI Vaccines Announces Poster Presentation at the 7th International Congenital CMV Conference & 17th International CMV Workshop  
  4. VBI Vaccines to Present at the Oppenheimer 29th Annual Healthcare Conference
  5. VBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 Financial Results
  6. VBI Vaccines Announces Third Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent GBM Patients
  7. VBI Vaccines Appoints Blaine McKee to Board of Directors
  8. VBI Vaccines Announces Phase 2 Clinical Study Design of its Prophylactic CMV Vaccine Candidate
  9. VBI Vaccines Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriter’s Option to Purchase Additional Shares for Aggregate Gross Proceeds of $42.9 Million
  10. VBI Vaccines Announces Pricing of $37.5 Million Public Offering
  11. VBI Vaccines Announces Proposed Public Offering of Common Shares
  12. VBI Vaccines Enters into License and Collaboration Agreement with Brii Biosciences for up to $129 Million plus Royalties to Develop a Functional Cure for Hepatitis B
  13. The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal
  14. VBI Vaccines Announces Third Quarter 2018 Financial Results and Provides Corporate Update